News
Market and company headlines
SRXHAll
Loading
04:00-16:00Oct 72 Stories
SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies
SPV, CERO 1236, to raise capital directly into subsidiary and not dilute existing SRX Global shareholders Proposed acquisition expected to accelerate development of CERo's lead product candidate, CER-1236, for hematologic malignancies NORTH PALM BEACH, Fla., Oct. 07, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strat
SRX Global Inks Stock Purchase Agreement With Cero Therapeutics; To Acquire All Outstanding Stock Of Cero Therapeutics
https://www.sec.gov/ix?doc=/Archives/edgar/data/1471727/000149315226046085/form8-k.htm
12:00-17:00Oct 62 Stories
SRX Global Commits $1.5 Million to Launch Family of AI-Powered ETFs through its EMJX Platform, Partnering with Kupa AI Co-Founder Andy Kim
SRX to dividend ETF holdings to shareholders Initial ETF to feature an actively managed digital asset hedging strategy powered by EMJX’s proprietary AI technology NORTH PALM BEACH, Fla., Oct. 06, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced a $1.5 million commitment to launch a new f
SRX Global Announces $1.5M Commitment To Roll Out New Family Of Actively Managed ETFs
SRX Global Inc. (NYSE American: SRXH) (the "Company" or "SRX"), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and